Current Report Filing (8-k)
March 09 2021 - 7:03AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): March 9, 2021
BRAIN
SCIENTIFIC INC.
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
333-209325
|
|
81-0876714
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
125
Wilbur Place, Suite 170
Bohemia,
NY 11716
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code: (917) 388-1578
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Not
applicable
|
|
Not
applicable
|
|
Not
applicable
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
Growth Company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item
7.01 Regulation FD Disclosure.
On
March 9, 2021, Brain Scientific Inc. issued a press release announcing that it received U.S. Food and Drug Administration (FDA)
510(k) clearance for its next generation NeuroCap™ device. NeuroCap™ is an advanced Electroencephalogram (EEG) electrode
array used to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired.
The
press release furnished as Exhibit 99.1 to this Current Report on Form 8-K is incorporated herein by reference. The information
in this Item 7.01 and in Exhibit 99.1 of Item 9.01 is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit
99.1 of Item 9.01.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date:
March 9, 2021
|
BRAIN
SCIENTIFIC INC.
|
|
|
|
By:
|
/s/
Boris Goldstein
|
|
Name:
|
Boris
Goldstein
|
|
Title:
|
Chairman
of the Board, Secretary and Executive Vice President
|
2
Brain Scientific (CE) (USOTC:BRSF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Brain Scientific (CE) (USOTC:BRSF)
Historical Stock Chart
From Aug 2023 to Aug 2024